Monitoring minimal/measurable residual disease in B-cell acute lymphoblastic leukemia by flow cytometry during targeted therapy

Liu, Zhiyu; Li, Yang; Shi, Ce

doi:10.1007/s12185-021-03085-y

Cited by 7 publications

(5 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been extensively studied and widely accepted that MRD status is an important prognostic factor in adult and pediatric B-ALL patients [12,13]. Currently, the most common methods to test MRD for B-ALL are qPCR and MFC with NGS emerging [13,14]. Comparing the test characteristics of MFC and NGS for B-ALL MRD will help to develop a future testing algorithm.…”

Section: Discussionmentioning

confidence: 99%

Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease

Momen

Tario

et al. 2023

J Hematopathol

View full text Add to dashboard Cite

Measurable residual disease (MRD) detection for precursor B-lymphoblastic leukemia (B-ALL) has become the standard of care. However, the testing methodology has not been standardized. We aim to correlate COG multiparameter flow cytometry (MFC) and ClonoSEQ techniques to assess the test characteristics, to study abnormal immunophenotype for B-ALL MRD, and to observe B-ALL clonal evolution and the impact of blinatumomab therapy on MFC testing. MFC and molecular reports were retrieved from electronic medical records and data was reviewed. Included in this study were 74 bone marrow samples collected from 31 B-ALL patients at our institution between January 2021 and March 2022. COG MFC and Clo-noSEQ results were concordant in 59/74 samples (80%) with positive concordant results in 12 samples (16%) and negative concordant results in 47 samples (64%). Discordant results were seen in 15/74 samples (20%), with 14 samples (19%) showing ClonoSEQ + /MFC-results and only 1 sample (1%) showing MFC + /ClonoSEQ-result. ClonoSEQ + /MFC-cases had MRD values ranging from 1 to 1400 cells/million nucleated cells with 86% of cases showing MRD values of < 100 cells/ million nucleated cells. Newly identified dominant sequences were detected using ClonoSEQ in 2/31 patients (6%) during follow-up. All 14 bone marrow samples from 8 patients, who had gone through blinatumomab immunotherapy, were MRD negative by MFC, but 3 cases were MRD positive by ClonoSEQ. Our results show strong correlation between COG MFC and ClonoSEQ (r = 0.96), and both methods are complementary. Clonal evolution may occur, and blinatumomab immunotherapy may impact MFC B-ALL MRD evaluation.

show abstract

Section: Discussionmentioning

confidence: 99%

Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease

Momen

Tario

et al. 2023

J Hematopathol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of Multiparameter Flow Cytometry and ClonoSEQ Studies for Precursor B-Lymphoblastic Leukemia Minimal Residual Disease Detection on Bone Marrow Samples

Nouran¹,

Joseph²,

Fu³

et al. 2023

Advances Leuk Res Treat

View full text Add to dashboard Cite

show abstract

“…Some studies have suggested extending FCM-MRD testing to other antigens expressed in early B-cell precursors (BCPs) besides CD19 to track B-ALL clones more sensitively. [65,[74][75][76] Cherian et al [76] explored new gate markers in B-ALL MRD analysis after CD19-targeted therapy. They employed the DFN approach, de ned the rough B-cell gate by identifying the expression of CD22 or CD24 (without CD66b), and combined it with markers aberrantly expressed in B-ALL, including CD10, CD20, CD34, CD38, and CD45, to differentiate abnormal B-lymphoid blast populations.…”

Section: Target-antigen-negative Relapsementioning

confidence: 99%

Current assessment and management of measurable residual disease in patients with acute lymphoblastic leukemia in the setting of CAR-T-cell therapy

Lin,

Zhao,

Chang

et al. 2023

Chin Med J

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR)-modified T-cell therapy has achieved remarkable success in the treatment of acute lymphoblastic leukemia (ALL). Measurable/minimal residual disease (MRD) monitoring plays a significant role in the prognostication and management of patients undergoing CAR-T-cell therapy. Common MRD detection methods include flow cytometry (FCM), polymerase chain reaction (PCR), and next-generation sequencing (NGS), and each method has advantages and limitations. It has been well documented that MRD positivity predicts a poor prognosis and even disease relapse. Thus, how to perform prognostic evaluations, stratify risk based on MRD status, and apply MRD monitoring to guide individual therapeutic decisions have important implications in clinical practice. This review assesses the common and novel MRD assessment methods. In addition, we emphasize the critical role of MRD as a prognostic biomarker and summarize the latest studies regarding MRD-directed combination therapy with CAR-T-cell therapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT), as well as other therapeutic strategies to improve treatment effect. Furthermore, this review discusses current challenges and strategies for MRD detection in the setting of disease relapse after targeted therapy.

show abstract

Monitoring minimal/measurable residual disease in B-cell acute lymphoblastic leukemia by flow cytometry during targeted therapy

Cited by 7 publications

References 53 publications

Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease

Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease

Comparison of Multiparameter Flow Cytometry and ClonoSEQ Studies for Precursor B-Lymphoblastic Leukemia Minimal Residual Disease Detection on Bone Marrow Samples

Current assessment and management of measurable residual disease in patients with acute lymphoblastic leukemia in the setting of CAR-T-cell therapy

Contact Info

Product

Resources

About